Quick and comprehensive information on psychotropic drugs for children and adolescents.
- Accurate and up-to-date
- Specific to children and adolescents
- Charts and tables help decision-making
- Icons and full color
More about this book:
The Clinical Handbook of Psychotropic Drugs for Children and Adolescents is a unique resource to help you make the right choices about psychotropic medications for younger patients. The fifth edition of this widely acclaimed reference has been fully updated and expanded.
- Updated information on psychiatric disorders in children and adolescents
- Unique comparison charts (dosages, side effects, pharmacokinetics, interactions...) that allow you to see at a glance which medication is the most suitable for each patient
- Instantly recognizable icons in full color throughout, allowing you to quickly find all the information you seek:
- General information on medications, availability, and indications
- Drug action, dosing, pharmacokinetics, and related areas
- Warnings and precautions
- Patient-related information, such as lab monitoring recommendations, nursing implications, and patient advice
- Clearly written patient and caregiver information sheets as printable pdf files
This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition:
- New chapters on Prescribing Safely and Ethically to Children and Adolescents, Pharmacogenetic Information for Common Psychotropic Drugs, and Aggression Management in Children and Adolescents
- Neuroscience-based nomenclature added to Product Availability tables
- Antipsychotic-Induced Extrapyramidal Side Effect (EPSE) chapter completely revised, plus new section on monitoring scales for EPSE
- Anxiolytics section on buspirone and benzodiazepine comparison table revised
- Mood Stabilizers chapter extensively revised
- Natural Health Products comprehensively revised
- New Unapproved Treatments revised, including preliminary evidence for cannabidiol and folinic acid for autism spectrum disorder and ketamine for mood disorder
- New agents: deutetrabenazine, ethopropazine, lemborexant, lumateperone, orphenadrine, tetrabenazine, valbenazine, viloxazine
- New formulations and trade names: Austedo, Caplyta, Dayvigo, Drizalma Sprinkle, Elepsia XR, Eprontia, Evekeo ODT, Gocovri, Hetlioz LQ, Ingrezza, Invega Hafyera, Jornay PM, Loreev XR, Lybalvi, Osmolex ER, Oxtellar XR, Parsitan, Perseris, Qelbree, Qudexy XR, Secuado, Spritam, Tyrvaya, Valtoco